{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:08:55Z","timestamp":1790014135878,"version":"4.0.1"},"reference-count":28,"publisher":"Weston Medical Publishing","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>Chronic opioid therapy for pain in sickle cell disease (SCD) carries risks of tolerance, hyperalgesia, and morbidity. Buprenorphine offers a safer alternative, yet optimal induction strategies for SCD patients dependent on full agonists remain unclear and traditionally require mild withdrawal prior to initiation. Three adult SCD patients transitioned from full opioid agonists (morphine equivalent daily dose 90-410 mg) to buprenorphine using a cross-titration strategy stratified by baseline opioid use to avoid withdrawal and maintain analgesia. These cases support an individualized buprenorphine induction approach that continues full agonists, expanding strategies to improve tolerability and transition success for adults with SCD.<\/jats:p>","DOI":"10.5055\/jom.1006","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:26:49Z","timestamp":1790011609000},"page":"425-431","source":"Crossref","is-referenced-by-count":0,"title":["Cross-titrating opioid agonists with buprenorphine for chronic pain in sickle cell disease"],"prefix":"10.5055","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1061-5431","authenticated-orcid":false,"given":"Jason S.","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared S.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"105759","doi-asserted-by":"crossref","unstructured":"Brandow AM, Carroll CP, Creary S, et al.: American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain. Blood Adv. 2020; 4(12): 2656-2701. DOI: 10.1182\/bloodadvances.2020001851.","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"105760","doi-asserted-by":"crossref","unstructured":"van Tuijn CFJ, Sins JWR, Fijnvandraat K, et al.: Daily pain in adults with sickle cell disease\u2014A different perspective. Am J Hematol. 2017; 92(2): 179-186. DOI: 10.1002\/ajh.24612.","DOI":"10.1002\/ajh.24612"},{"key":"105761","doi-asserted-by":"crossref","unstructured":"Smith WR, Penberthy LT, Bovbjerg VE, et al.: Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008; 148(2): 94-101. DOI: 10.7326\/0003-4819-148-2-200801150-00004.","DOI":"10.7326\/0003-4819-148-2-200801150-00004"},{"key":"105762","doi-asserted-by":"crossref","unstructured":"Han J, Zhou J, Saraf SL, et al.: Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug. 2018; 27(5): 479-486. DOI: 10.1002\/pds.4291.","DOI":"10.1002\/pds.4291"},{"key":"105763","doi-asserted-by":"crossref","unstructured":"Lee M, Silverman SM, Hansen H, et al.: A comprehensive review of opioid-induced hyperalgesia. Pain Phys. 2011; 14(2): 145-161.","DOI":"10.36076\/ppj.2011\/14\/145"},{"key":"105764","doi-asserted-by":"crossref","unstructured":"Liu SA, Brown TR, King AA, et al.: Opioid-related emergency admissions in people with opioid dependence\/use disorder with and without sickle cell disease: An analysis of multi-state insurance claims. Gen Hosp Psychiatry. 2024; 91: 83-88. DOI: 10.1016\/j.genhosppsych.2024.09.013.","DOI":"10.1016\/j.genhosppsych.2024.09.013"},{"key":"105765","doi-asserted-by":"crossref","unstructured":"Bode AL, Borja-Montes OF, Quazi MA, et al.: Sickle cell disease and opioid overdose outcomes in the United States: A nationwide analysis. Ann Hematol. 2025; 104(3): 1551-1561. DOI: 10.1007\/s00277-025-06236-x.","DOI":"10.1007\/s00277-025-06236-x"},{"key":"105766","doi-asserted-by":"crossref","unstructured":"Jonassaint CR, O\u2019Brien J, Nardo E, et al.: Prevalence of substance use disorders in sickle cell disease compared to other chronic conditions: A population-based study of Black American adults. J Gen Intern Med. 2023; 38(5): 1214-1223. DOI: 10.1007\/s11606-022-07786-w.","DOI":"10.1007\/s11606-022-07786-w"},{"key":"105767","doi-asserted-by":"crossref","unstructured":"Prince E, Loeser P, Early M, et al.: \u201cBuprenorphine, it works so differently\u201d: Adults with sickle cell disease describe transitioning to buprenorphine for treatment of chronic pain. J Pain. 2024; 25(3): 632-641. DOI: 10.1016\/j.jpain.2023.09.014.","DOI":"10.1016\/j.jpain.2023.09.014"},{"key":"105768","doi-asserted-by":"crossref","unstructured":"Carroll CP, Prince EJ, Lauriello A, et al.: Acute pain treatment in patients with sickle cell disease transitioned to buprenorphine: Evidence of equivalent pain relief. J Sickle Cell Dis. 2025; 2(1): yoaf014. DOI: 10.1093\/jscdis\/yoaf014.","DOI":"10.1093\/jscdis\/yoaf014"},{"key":"105769","doi-asserted-by":"crossref","unstructured":"Gregory C, Yadav K, Linders J, et al.: Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Addiction. 2025; 120(1): 7-20. DOI: 10.1111\/add.16646.","DOI":"10.1111\/add.16646"},{"key":"105770","doi-asserted-by":"crossref","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, et al.: Use of micro-doses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Subst Abuse Rehabil. 2016; 7: 99-105. DOI: 10.2147\/SAR.S109919.","DOI":"10.2147\/SAR.S109919"},{"key":"105771","doi-asserted-by":"crossref","unstructured":"Buchheit BM, Joslin T, Turner HN, et al.: Ambulatory micro-dose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease. Pediatr Blood Cancer. 2021; 68(1): e28766. DOI: 10.1002\/pbc.28766.","DOI":"10.1002\/pbc.28766"},{"key":"105772","doi-asserted-by":"crossref","unstructured":"Irwin M, Gunther W, Keefer P, et al.: Buprenorphine for chronic pain in a pediatric patient with sickle-cell disease. J Pain Symptom Manage. 2021; 62(5): 1086-1091. DOI: 10.1016\/j.jpainsymman.2021.04.007.","DOI":"10.1016\/j.jpainsymman.2021.04.007"},{"key":"105773","doi-asserted-by":"crossref","unstructured":"David MS, Jones J, Lauriello A, et al.: Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization. Am J Hematol. 2022; 97(11): 1435-1442. DOI: 10.1002\/ajh.26699.","DOI":"10.1002\/ajh.26699"},{"key":"105774","doi-asserted-by":"crossref","unstructured":"Leyde S, Suen L, Pratt L, et al.: Transition from oxycodone to buprenorphine\/naloxone in a hospitalized patient with sickle cell disease: A case report. J Gen Intern Med. 2022; 37(5): 1281-1285. DOI: 10.1007\/s11606-021-07295-2.","DOI":"10.1007\/s11606-021-07295-2"},{"key":"105775","doi-asserted-by":"crossref","unstructured":"Torres C, Galadanci N, Osborn J, et al.: Real-world implementation of the David-Carroll buprenorphine protocol for pain management in sickle cell disease. Am J Hematol. 2024; 99(9): 1834-1836. DOI: 10.1002\/ajh.27407.","DOI":"10.1002\/ajh.27407"},{"key":"105776","doi-asserted-by":"crossref","unstructured":"Jacobs-McFarlane C, Liu A, McCrary B, et al.: Buprenorphine is associated with lower home opioid use and acute care utilization in sickle cell disease. Pain Manag Nurs. 2025; 26: 585-591. DOI: 10.1016\/j.pmn.2025.04.012.","DOI":"10.1016\/j.pmn.2025.04.012"},{"key":"105777","doi-asserted-by":"crossref","unstructured":"Patel A, Kalmus G, Dampier C, et al.: Treatment experience using a micro-induction buprenorphine protocol for chronic pain in pediatric sickle cell disease. Pediatr Blood Cancer. 2025; 72(8): e31731. DOI: 10.1002\/pbc.31731.","DOI":"10.1002\/pbc.31731"},{"key":"105778","doi-asserted-by":"crossref","unstructured":"deBettencourt J, Nagy M, Rotman C, et al.: Buprenorphine for children and adolescents with sickle cell disease: A scoping review. Children (Basel). 2026; 13(3): 388. DOI: 10.3390\/children13030388.","DOI":"10.3390\/children13030388"},{"key":"105779","doi-asserted-by":"crossref","unstructured":"Spreen LA, Dittmar EN, Quirk KC, et al.: Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Pharmacotherapy. 2022; 42(5): 411-427. DOI: 10.1002\/phar.2676.","DOI":"10.1002\/phar.2676"},{"key":"105780","doi-asserted-by":"crossref","unstructured":"Ito S, Welsh M, Bockman C, et al.: Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis. J Opioid Manag. 2023; 19(6): 543-554. DOI: 10.5055\/jom.0839.","DOI":"10.5055\/jom.0839"},{"key":"105781","doi-asserted-by":"crossref","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, et al.: Micro-induction of buprenorphine\/naloxone: A review of the literature. Am J Addict. 2021; 30(4): 305-315. DOI: 10.1111\/ajad.13135.","DOI":"10.1111\/ajad.13135"},{"key":"105782","doi-asserted-by":"crossref","unstructured":"Hayes BT, Li P, Nienaltow T, et al.: Low-dose buprenorphine initiation and treatment continuation among hospitalized patients with opioid dependence: A retrospective cohort study. J Subst Use Addict Treat. 2024; 158: 209261. DOI: 10.1016\/j.josat.2023.209261.","DOI":"10.1016\/j.josat.2023.209261"},{"key":"105783","doi-asserted-by":"crossref","unstructured":"Edinoff AN, Fahmy OH, Spillers NJ, et al.: Low-dose initiation of buprenorphine: A narrative review. Curr Pain Headache Rep. 2023; 27(7): 175-181. DOI: 10.1007\/s11916-023-01116-3.","DOI":"10.1007\/s11916-023-01116-3"},{"key":"105784","doi-asserted-by":"crossref","unstructured":"Chambers LC, Hallowell BD, Zullo AR, et al.: Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open. 2023; 6(9): e2334540. DOI: 10.1001\/jamanetworkopen.2023.34540.","DOI":"10.1001\/jamanetworkopen.2023.34540"},{"key":"105785","doi-asserted-by":"crossref","unstructured":"Suen LW, Chiang AY, Jones BLH, et al.: Outpatient low-dose initiation of buprenorphine for people using fentanyl. JAMA Netw Open. 2025; 8(1): e2456253. DOI: 10.1001\/jamanetworkopen.2024.56253.","DOI":"10.1001\/jamanetworkopen.2024.56253"},{"key":"105786","doi-asserted-by":"crossref","unstructured":"Cohen SM, Weimer MB, Levander XA, et al.: Low dose initiation of buprenorphine: A narrative review and practical approach. J Addict Med. 2022; 16(4): 399-406. DOI: 10.1097\/ADM.0000000000000945.","DOI":"10.1097\/ADM.0000000000000945"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4146\/4423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/4146\/4423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:27:00Z","timestamp":1790011620000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/4146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.1006","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}